The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study

Zhang, Chenghai; Wu, Binghong; Yang, Hong; Yao, Zhendan; Zhang, Nan; Tan, Fei; Liu, Maoxing; Xu, Kai; Chen, Lei; Xing, Jiadi; Cui, Ming; Su, Xiangqian

doi:10.1186/s12885-022-10230-1

BMC Cancer

Article metrics
Last updated: Thu, 25 Apr 2024 15:16:18 Z

The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study

Access & Citations

1034

Article Accesses
0

Web of Science
0

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com